Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Label Battles: Beovu And Eylea Contest Begins In AMD

Novartis's injectable anti-VEGF Beovu was approved for wet AMD by the US FDA

Executive Summary

Shares in Eylea-maker Regeneron slid after FDA approved Novartis's competing VEGF inhibitor for treating AMD, but some observers said investors had overreacted.

You may also be interested in...



Novartis Pharma President Marie-France Tschudin On Inclisiran, Launches And More

Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.

Iveric's Zimura Succeeds In Dry AMD Study

The New York-headquartered  firm, which recently decided to focus on gene therapy, has to decide whether to partner Zimura or go it alone.

Roundup Lawsuits Overshadow Pharma Growth At Bayer

Pharmaceutical sales hit €4.35bn helped by a strong showing in China but as the number of glyphosate plaintiffs in the US jumps to 42,700, the German group's priority is sorting out Monsanto.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125988

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel